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Supplementary feeding with either ready-to-use fortified
spread or corn-soy blend in wasted adults starting
antiretroviral therapy in Malawi: randomised, investigator
blinded, controlled trial
MacDonald J Ndekha, nutritionist,1 Joep J G vanOosterhout, associate professor,2 Eduard E Zijlstra, professor,2
Micah Manary, student,4 Haroon Saloojee, research physician,3 Mark J Manary, professor and senior
scientist1,4,5
ABSTRACT
Objective To investigate the effect of two different food
supplements on body mass index (BMI) in wasted
Malawian adults with HIV who were starting antiretroviral
therapy.
Design Randomised, investigator blinded, controlled
trial.
Setting Large, public clinic associated with a referral
hospital in Blantyre, Malawi.
Participants 491 adults with BMI <18.5.
Interventions Ready-to-use fortified spread (n=245) or
corn-soy blend (n=246).
Main outcome measures Primary outcomes: changes in
BMI and fat-free body mass after 3.5 months. Secondary
outcomes: survival, CD4 count, HIV viral load, quality of
life, and adherence to antiretroviral therapy.
Results The mean BMI at enrolment was 16.5. After
14weeks, patients receiving fortified spreadhad a greater
increase in BMI and fat-free body mass than those
receiving corn-soy blend: 2.2 (SD 1.9) v 1.7 (SD 1.6)
(difference 0.5, 95% confidence interval 0.2 to 0.8), and
2.9 (SD 3.2) v 2.2 (SD 3.0) kg (difference 0.7 kg, 0.2 to
1.2 kg), respectively. Themortality rate was 27% for those
receiving fortified spread and 26% for those receiving
corn-soy blend. No significant differences in the CD4
count, HIV viral load, assessment of quality of life, or
adherence to antiretroviral therapy were noted between
the two groups.
Conclusion Supplementary feeding with fortified spread
resulted in a greater increase in BMI and lean body mass
than feeding with corn-soy blend.
Trial registration Current Controlled Trials
ISRCTN67515515.
INTRODUCTION
The prevalence of wasting, defined as a body mass
index (BMI) <18.5, in adults with advancedHIV infec-
tion in sub-SaharanAfrica is 20-40%.12Wasting can be
the result of inadequate nutrient intake, either from
anorexia or food insecurity associated with poverty, a
catabolic state induced by opportunistic infection or
malignancy, or poor absorption of nutrients secondary
to diarrhoea andmalabsorption. Because food insecur-
ity is common in sub-Saharan Africa3-5 and an ade-
quate diet is believed to be important for adherence
to antiretroviral therapy67 supplementary feeding in
conjunction with treatment is advocated as standard
in the care of wasted adults with HIV in Malawi. In
sub-Saharan Africa mortality during the first months
of antiretroviral therapy settings is high, and a low
BMI is an independent risk factor for this early
mortality.8 Supplementary feeding might therefore
improve outcomes in patients receiving antiretroviral
therapy because it ameliorates food insecurity. Evi-
dence to support the effectiveness of this practice, how-
ever, is limited, and there have been no published
controlled trials showing the benefit of such food sup-
plementation in settings with limited resources,
whether people are receiving antiretroviral therapy or
not.9
The most commonly available supplementary food
in food aid programmes is corn-soy blended flour, an
inexpensive fortified cereal-legume combination that
requires cooking and has been widely used in Africa
for decades. Corn-soy blend, however, has been asso-
ciated with disappointing results in supplementary
feeding programmes among children, pregnant
women, and adults with HIV in sub-Saharan
Africa.10 11 In a recent study in urban Malawi among
adults with late stage HIV infection who were not
receiving antiretroviral therapy, corn-soy blend had
no effect on mortality or clinical complications.12 Spe-
cialised, energy dense ready-to-use fortified spreads
have also been recommended for feeding wasted
adults with HIV. This spread is a pre-cooked, energy
dense, lipid paste made from peanuts that resists bac-
terial contamination.13 A fortified spread has been for-
mulated to deliver the same nutrients as themilk based
therapeutic food F-100 for severelymalnourished chil-
dren, and its use has been associated with better
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outcomes in therapeutic and supplementary feeding of
malnourished children with and without HIV.14 15
We conducted a randomised, investigator blinded
controlled supplementary feeding trial in Malawi to
test the hypothesis that among wasted adults with
HIV starting antiretroviral therapy, patients who
receive the fortified spread for 14 weeks will have a
greater increase in BMI and fat-free body mass than
those receiving corn-soy blend.
METHODS
Participants and study site
Eligible participants were all adults aged 18 or over
with HIV who met the eligibility criteria for anti-
retroviral therapy according to the Malawian national
HIV treatment guidelines (WHO clinical stage III or
IV or any WHO stage with a CD4 count <250/mm3)
and who were starting treatment with a BMI <18.5.
Exclusion criteriawere pregnancy and lactationor par-
ticipation in another supplementary feeding pro-
gramme. The study took place at the antiretroviral
therapy clinic of Queen Elizabeth Central Hospital in
Blantyre, Malawi, from January 2006 to April 2007.
Blantyre is the major commercial city of Malawi,
with a population of 1 000 000 and an estimated HIV
prevalence of 27% in adults in 2004.16 Clinical care for
adults at this clinic is provided by the department of
medicine of the College of Medicine, University of
Malawi. The only available first line antiretroviral ther-
apy regimen is a generic, fixed dose combination of
nevirapine, stavudine, and lamivudine. Routine pro-
phylaxis with co-trimoxazole before and during anti-
retroviral therapy had not been fully implemented at
the time of the study. It was approved as a standard
treatment by the Ministry of Health in 2006, but the
logistics to implement this policy were not in place
until 2007.
Study design
This was a randomised, investigator blinded, con-
trolled effectiveness trial of supplementary feeding
with either corn-soy blend or fortified spread. Rando-
misation took place with sealed, unmarked opaque
envelopes that were allocated to participants in an
area separate from the research and treatment room
by using block randomisation of 50 numbers. The
envelopes contained a card with a unique number
from 1 to 500. A designated staff member matched
the number with the food assignment and dispensed
the appropriate food during the intervention period.
Participants were not blinded to the food assignment
because the blended flour was distinct in appearance
compared with the peanut paste. All the other staff
members, including the clinicians managing the anti-
retroviral therapy programme and the nutritionist,
were blinded to the dietary assignment. The food sup-
plements were distributed monthly in conjunction
with clinic follow-up visits, and each of the study parti-
cipants remained within the group to which they were
assigned for the duration of the study. Food supple-
ments were started at the same time as antiretroviral
therapy and given for a period of 14 weeks. Partici-
pants returned for follow-up two weeks after the start
of the study and monthly thereafter.
Our primary outcomeswere changes in theBMI and
the fat-free body mass after 14 weeks. Secondary out-
comes were nutritional status, defined as well nour-
ished (BMI ≥18.5), moderately wasted (BMI 16-
<18.5), severely wasted (BMI <16), death, alive/nutri-
tional status unknown, and lost to follow-up. Addi-
tional secondary outcomes were quality of life, serum
albumin concentration, haemoglobin concentration,
CD4 count, HIV viral load, and adherence to anti-
retroviral therapy.
The sample size of 450 enabled detection of a differ-
ence in BMI and fat-free body mass of 0.5 kg between
the two groups with 95% specificity and 80% power.
We allowed for 15% attrition because of pregnancy,
losses to follow-up, and death.
Study procedures
On enrolment, we obtained informed consent and
demographic, clinical status, quality of life, and anthro-
pometric measurements; measurements included
weight, height, mid-upper arm circumference, waist
circumference, and bioelectrical impedance. Partici-
pants had their bioelectrical impedance measured
when they presented to the clinic for care, without
regard to ambient conditions or the time of day.
Those who seemed clinically ill were assumed to be
at risk for dehydration, and a bioelectrical impedance
measurement was not recorded.
Clinical officers supervised provision of anti-
retroviral therapy. Participants were subsequently
seen at the clinic on four occasions during the study:
after two, six, 10, and 14 weeks. During each visit
Assessed for eligibility  (n=1343)
Excluded  (n=852):  
 Not meeting inclusion criteria,  
 BMI >18.5  (n=832)   
 Refused to participate (n=11)   
 Missed as eligible (n=5)   
 Pregnant   (n=4)
Analysed (n=156)
No one excluded from analysis
Did not complete 3.5 month
follow-up (n=89):  
 Died (n=67)  
 Alive, nutritional status 
 unknown (n=11)  
 Lost, status unknown (n=11)
Allocated and received ready-to-use 
fortified spread  (n=245)
Did not complete 3.5 
month follow-up (n=80)  
 Died (n=64)  
 Alive, nutritional status 
 unknown (n=10)  
 Lost, status unknown (n=6)
Allocated and received 
corn-soy blend (n=246)
Analysed (n=166)
No one excluded from analysis
Allocation
Analysis
Follow-up
Randomised (n=491)
Enrolment
Fig 1 | Study flow diagram
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trained study staff assessed clinical status, administered
questionnaires on quality of life and adherence to anti-
retroviral therapy, and measured body weight, bioe-
lectrical impedance, and waist and mid-upper arm
circumferences. They collected information on quality
of life with a locally adapted version of the 14 item
CDChealth related quality of life assessment.17 Adher-
ence to treatment was measured with a local, pre-
viously validated questionnaire that consisted of four
questions: did you miss a tablet the day, week, month,
or ever before.18 Bioelectrical impedance measure-
ments were done with the Quaatum 2000 device
(RJL Systems, Clinton Township, Michigan). All mea-
surements were carried out with standardised proce-
dures.
Researchers took blood samples at enrolment and at
14 weeks to measure serum albumin concentration,
haemoglobin concentration, CD4 count (FacsCount,
Becton-Dickinson, Franklin Lakes, NJ, USA), and
HIV viral load (Roche Amplicor; Roche, Basel. Swit-
zerland; detection level 48 copies/ml).
Participants’diets on enrolmentwere assessedwith a
24 hour dietary recall the day before enrolment. In
addition, for each of the foods that the participants con-
sumed the day before enrolment they were asked
whether the foods were consumed daily, weekly, or
monthly. Dietary intakes were assessed with three dif-
ferent methods: the total number of different foods
consumed, whether animal products were consumed
or not, and a 12 point dietary diversity score that has
previously been validated and correlated with house-
hold food security.19
Participants who failed to return for a scheduled
clinic visit for antiretroviral therapy were visited at
home within two months, and information regarding
clinical status, compliance with treatment, and body
weight and composition was collected. If the partici-
pant had died, the date and circumstances of death
were ascertained by interviews with the closest rela-
tives. Participants who could not be located were con-
sidered lost to follow-up.
After the supplementary feeding period ended social
scientists from theUniversity ofMalawi, who were not
involved in any other aspect of the study, led open
ended focus group discussions to explore the use,
acceptability, and sharing of the food supplements
and to assess dietary compliance; groups averaged
eight randomly selected study participants from both
supplementary feeding groups.
Study foods
Table 1 shows the nutritional compositions of the two
supplementary foods. Both supplementary foods pro-
vided the same level of energy because different
amounts were used; the energy per unit higher in the
fortified spread; neither provided amounts ofmicronu-
trients that significantly exceeded the estimated aver-
age requirement. The supplements were produced
locally in accordance with international food safety
specifications. The ready-to-use fortified spread was
supplied in 245 g plastic bottles, and participants
received one bottle a day. The amounts of each supple-
ment given provided about 50% of the daily estimated
average energy requirement, based on WHO nutri-
tional guidelines that take into account that sympto-
matic adults with HIV/AIDS need 30% more energy
than healthy individuals. 20 Both groups of participants
were advised to consider the food supplements as part
of theirmedical treatment and told that the food should
not be shared with others.
Statistical analysis
The data were doubly entered on an Excel database.
We calculated fat-free body mass using the equations
developed byKotler et al for wasted adults withHIV.21
These equations were used in our setting without vali-
dation. We calculated means and standard deviations
for continuous parameters and used Fisher’s exact test
(two outcomes) or χ2 test (three or more outcomes) to
compare dichotomous variables between participants
in each supplement group. We used Student’s t test to
compare continuous variables. P<0.05 was considered
significant for all comparisons.
BMI was measured at four subsequent points after
enrolment (after two, six, 10, and 14 weeks), so the
participant’s recovery was assessed during each of
these four distinct time intervals. We calculated the
rate of change in BMI during each of these intervals
for each participant. To determine whether the rates
of change in BMI during the 14 week feeding period
differed between the two food groups, we compared
the mean change in BMI during each interval for
each food group using Student’s t test. Weight gain
Table 1 | Nutrients provided by two food supplements, expressed as amount per day and
compared with estimated average requirement (EAR) for adults
Fortified spread
(245 g/day)
Corn-soy blended flour
(374 g/day)
EAR
Women Men
Energy (kJ) 5694 5694 13 252 13 252
Protein (g) 35.5 50 46 56
Fat (g) 91 26.2 — —
Calcium (mg) 830 258 1000 1000
Phosphorus (mg) 700 1050 580 580
Magnesium (mg) 240 500 255 330
Potassium (mg) 2880 1700 4700 4700
Selenium (μg) 78 22 45 45
Zinc (mg) 8 8 8 11
Copper (mg) 0.9 2.9 0.9 0.9
Iron (mg) 8 16 18 8
Vitamin A (μg) 710 1040 700 700
Vitamin C (mg) 90 26 60 75
Vitamin D (μg) 5 6 5 5
Vitamin E (mg) 52 32.5 12 12
Niacin (mg) 14 13 11 12
Folic acid (μg) 400 153 320 320
Thiamine (mg) 1.1 1.3 0.9 1.0
Riboflavin (mg) 1.3 0.8 0.9 1.1
Vitamin B-6 (mg) 1.3 1 1.1 1.1
Vitamin B-12 (μg) 1.4 0.5 2.0 2.0
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during recovery from wasting follows an exponential
decay pattern22; when individuals are more wasted
they regain weight faster, and as they approach a nor-
mal BMI, the rate of weight gain decreases. Given this,
we used the mean values for change in BMI for each
food group from this study to determine the shape of
the BMI recovery curve, using an exponential model-
ing program (GraphPad Prism 3.03).
We assessed the association between death and
demographic, anthropometric, and immunological
characteristics by Cox regression modeling. The cov-
ariates considered were sex, age, type of supplemen-
tary food, receipt of co-trimoxazole, BMI, fat-free
body mass, CD4 count, haemoglobin concentration,
and albumin concentration at enrolment. Participants
who were given co-trimoxazole as prophylaxis at any
time during the study period were considered as hav-
ing received it in the regression analysis. SPSS version
13.0 (Chicago, IL) statistical software was used.
Participants were stratified into thirds for the three
different measures of dietary intake, and we compared
the change in BMI for those receiving fortified spread
and corn-soy blend between each third to determine
whether supplementary feeding was more beneficial
among participants with more food insecurity.
RESULTS
We enrolled 491 participants (97%) of all eligible indi-
viduals during the study period) (fig 1). There were no
significant differences in the demographic, anthropo-
metric, or clinical characteristics between the two study
groups at baseline (table 2). Seventeen (3.4%) partici-
pantswere lost to follow-up, and 21 (4.3%)were known
tobe alive butmissed their 3.5month clinic visit andno
anthropometric measurements were made. No
adverse reactions to either food were reported.
After 14 weeks of nutritional intervention and anti-
retroviral therapy participants who received fortified
spread had a greater increase in BMI, fat-free body
mass, and mid-upper arm circumference than those
who received corn-soy blend (table 3). Fat-free mass
contributed to 2.9 kg (51.8%) of the 5.6 kg weight
gain in the fortified spread group and 2.2 kg (51.2%)
of the 4.3 kg weight gain in the corn-soy blend group.
There were no significant differences in survival, HIV
viral load strata, CD4 count, or quality of life between
the groups.
Mortality was high in both groups: 131 (27%) parti-
cipants died within the first 14 weeks. Male sex, not
receiving co-trimoxazole prophylaxis, and a lower
BMI, haemoglobin, or albumin on enrolment were
independent risk factors of death at 14 weeks (table 4).
Self reported adherence to antiretroviral therapy
was similar in both groups at each follow-up visit.
Few participants reported missing a dose on the pre-
vious day (3/167 (1.8%) v 2/176 (1.2%), P=0.5) or at
least one dose in the previous week (8/167 (4.8%) v 8/
176 (4.5%), P=0.5) in the fortified spread and corn-soy
blend groups, respectively.
Mathematical modelling of change in BMI between
each measurement interval in each group showed that
the coefficient in the exponential term in the twomod-
els was similar (fig 2). Thus the rate of change in BMI
decreased during the supplementation period (fig 2),
but the change in BMI was greater by a constant
amount in the fortified spread group (0.045) compared
with the corn-soy blend group throughout the entire
supplementation period. Exponential decay models
fit both datasets well (r2=0.98), although these datasets
consist of only four points.
We examinedoutcomes in subgroups of participants
stratified by the quality of their diet on enrolment and
the type of supplementary feeding (table 5). Neither
corn-soyblendnor fortified spread affected anydietary
subgroup differently; diet on enrolment had no effect
on outcome or on the benefit of either supplement.
Ninety five participants attended 12 focus group dis-
cussion sessions; 42 of whom received fortified spread
and 53 corn-soy blend. Both study food supplements
were universally highly appreciated. Nearly all partici-
pants said that sharing of both food supplements by
dependents and family members was common,
although corn-soy blend was more likely to be shared
because it needed preparation by caregivers before
consumption.
DISCUSSION
In wasted patients starting antiretroviral therapy, food
supplementation with ready-to-use fortified spread
resulted in a greater increase in BMI, fat-free body
Table 2 | Initial status of wasted adults with HIV starting antiretroviral therapy. Figures are
means (SD) unless stated otherwise
Fortified spread (n=245) Corn-soy blend (n=246)
Demographics:
Age (years) 36.0 (11.0) 36.0 (12.0)
No (%) of women 152 (62) 142 (58)
Anthropometric:
BMI 16.5 (1.5) 16.5 (1.5)
Fat-free mass (% of body composition) 96.0 (10.0) 95.0 (12.0)
Fat-free body mass (kg) 40.5 (5.8) 41.0 (7.2)
Mid-upper arm circumference (cm) 20.4 (2.2) 20.8 (4.1)
Waist circumference (cm) 65.8 (5.2) 65.8 (3.2)
No (%) by nutritional status:
Severely malnourished (BMI <16.0) 81 (33) 81 (33)
Moderately malnourished (BMI 16.0-18.5) 164 (67) 165 (67)
Laboratory results:
CD4 count (cells ×106/l) 131.0 (140.0) 142.0 (319.0)
Albumin (g/l) 24.0 (8.0) 24.0 (4.0)
Haemoglobin (g/l) 96 (20) 98 (57)
No (%) who received co-trimoxazole prophylaxis 151 (62) 137 (56)
Quality of life:
General health (1=excellent, 5=poor) 4.5 (0.7) 4.5 (0.8)
Physically unhealthy days/month 17.6 (11.8) 16.2 (11.3)
Mentally unhealthy days/month 6.1 (9.4) 6.4 (10.0)
Mental/physical limitation days/month 12.7 (12.9) 13.2 (13.1)
Diet:
Dietary diversity score (range 0-12) 2.9 (1.4) 2.8 (1.4)
No (%)who consumedanimal productswithin 24hrs 66 (26) 62 (25)
No of different foods consumed within 24 hrs 8.6 (4.0) 7.8 (3.7)
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mass, andmid-upper arm circumference than corn-soy
blend after 14 weeks. There were, however, no differ-
ences observed inmortality, CD4 count,HIV suppres-
sion, adherence to antiretroviral therapy, or quality of
life between the groups. Weight gain with supplemen-
tary feedingwas considerable, resulting in gains of 10%
and 13% of initial body mass for corn-soy blend and
fortified spread, respectively.
Limitations and major findings
Our study was limited in that food consumption was
not observed in either of the groups, therefore we do
not know the degree of adherence with the dietary
recommendations. However, this was an effectiveness
study, as opposed to an efficacy study, to determine
which of the two supplementary foods leads to better
outcomes when provided to patients in an operational
setting with limited resources. As we did not have a
control group of participants receiving no supplemen-
tary food, we do not know what the nutritional status
would have been without supplementary feeding.
Although we included a control group in the original
proposal, this was deemed unethical by the review
board in Malawi because it is national policy to give
supplementary food to wasted patients with HIV/
AIDS. Given that the benefits of a specialised energy-
dense supplementary food were limited to improved
nutritional status, these results highlight the need for
a randomised controlled trial of the provision of sup-
plementary food to wasted adults with HIV compared
with the provision of no food to understand what ben-
efits supplementary feeding of any type confers. Only
3% of participants were lost to follow-up, which is low
compared with other studies of individuals with HIV
in sub-Saharan Africa.
The analysis of the change in BMI with time indi-
cates that during every interval in the 14 weeks study
period, participants receiving fortified spread gained
more BMI than those receiving corn-soy blend. This
suggests that fortified spread conferred a differential
benefit to participants over corn-soy blend throughout
the entire study period, rather simply in the first few
weeks.
In Africa antiretroviral therapy, particularly regi-
mens including stavudine, is associated withmetabolic
side effects such as lipodystrophy, dyslipidaemias, and
insulin resistance in individuals with BMI ≥25.23
Ready-to-use fortified spread is a food with a high fat
content.We chose to give the supplementary food for a
short, fixed duration of 14 weeks, to avoid putting
patients who would have recovered from their wasting
at an increased risk of metabolic complications.
Fat-free mass contributed about the same fraction of
the weight gain in each food group, suggesting that
more of the fortified spread was consumed than corn-
soy blend. Fortified spread might have promoted
greater weight gain than corn-soy blend because of its
higher energy density, thereby allowing adequate
energy intake in patientswith somedegree of anorexia.
In addition, the focus group discussions indicated that
fortified spread was shared less often. Fortified spread
is ready to be eaten, while corn-soy blend needs to be
cooked. Food preparation for ill adults with HIV/
Table 3 | Outcomes in wasted adults with HIV at 14 weeks. Figures are means (SD) unless
stated otherwise
Fortified spread
(n=245)
Corn-soy blend
(n=246)
Difference
(95% CI)
Anthropometric:
Gain in BMI 2.2 (1.9) 1.7 (1.7) 0.5 (0.2 to 0.8)
Gain in fat-free body mass (kg) 2.9 (3.2) 2.2 (3.0) 0.7 (0.2 to 1.2)
Gain in mid-upper arm circumference (cm) 2.2 (2.0) 1.6 (1.7) 0.6 (0.3 to 0.9)
Weight gain (kg) 5.6 (4.8) 4.3 (4.0) 1.3 (0.5 to 2.1)
BMI (kg/m2) 19.0 (2.1) 18.4 (1.1) 0.6 (0.3 to 0.9)
Fat-free body mass (% of body composition) 89.0 (8.0) 91.0 (8.0) 2.0 (0.6 to 3.4)
No (%) by clinical/nutritional status:
Severely malnourished 10 (4) 12 (5) −1 (−5 to 2)
Moderately malnourished 53 (22) 69 (28) −6 (−14 to 1)
Well nourished 93 (38) 85 (35) 3 (−5 to 12)
Died 67 (27) 64 (26) 1 (−6 to 9)
Alive nutritional status unknown 11 (4) 10 (4)
Lost to follow-up 11 (4) 6 (2)
Admitted to hospital in first 12 weeks 30 (12) 31 (13) −1 (−6 to 5)
Laboratory results:
CD4 count (cells×106/l) 289 (185) 297 (447) −8 (−69 to 53)
Increase in CD4 count (cells×106/l) 168 (145) 150 (139) 18 (−7 to 43)
No (%) by HIV viral load:
<50 copies/ml 96 (39) 97 (39)
P=0.98 for
trend
50-1000 copies/ml 59 (24) 62 (25)
>1000 copies/ml 5 (2.0) 4 (1.6)
Serum albumin (g/l) 32 (7) 32 (10) 0 (−2 to 2)
Increase in serum albumin (g/l) 6 (7) 6 (3) 0 (−1 to 1)
Haemoglobin (g/l) 112 (17) 113 (15) −1 (−4 to 2)
Increase in haemoglobin (g/l) 15 (21) 13 (20) 2 (−2 to 6)
Quality of life:
General health (1=excellent, 5=poor) 3.1 (1.0) 3.0 (1.0) 0.1 (−0.1 to 0.3)
Physically unhealthy days/month 5.5 (8.0) 5.7 (8.4) −0.2 (−1.7 to 1.3)
Mentally unhealthy days/month 2.6 (5.5) 2.5 (5.7) 0.1 (−0.9 to 1.1)
Mental/physical limitation days/month 4.2 (8.8) 4.2 (8.8) 0 (−1.6 to 1.6)
Table 4 | Summary of mutually adjusted Cox regression
modelling of death†
Independent variable Hazard ratio‡ (95% CI)
Male sex 1.75 (1.32 to 2.31)*
Age (years) 1.01 (1.00 to 1.02)
BMI 0.82 (0.76 to 0.89)*
Fat-free body mass (kg) 0.99 (0.97 to 1.02)
No co-trimoxazole prophylaxis§ 1.61 (1.29 to 2.01)*
CD4 count (cells ×106/l) 1.00 (0.99 to 1.01)
Haemoglobin (g/l) 0.88 (0.83 to 0.94)*
Albumin (g/l) 0.45 (0.37 to 0.55)*
Received fortified spread 0.91 (0.73 to 1.14)
*P<0.05.
†Enter mode used (that is, model includes all independent variable
specified at onset) χ2=226, df=9, for model, P<0.001.
‡Exponentiated β coefficient corresponds to hazard ratio, which
corresponds to factor by which chance of death increases with increase
in 1 unit in independent variable. Hazard ratio <1 indicates that as
independent variable decreases, risk of death increases.
§Did not receive co-trimoxazole prophylaxis at any time during study
period.
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AIDS will often be done by relatives or dependents, a
practice thatmight bemore conducive to sharing of the
supplementary food. Corn-soy blend is similar to com-
ponents of the traditional diet, while fortified spread is
regarded as a special supplement for patients, a medic-
inal food. This cultural view of supplementary foods
might have encouraged greater sharing of corn-soy
blend.
Thehabitual diets of the participantswere poor; only
30% achieved a dietary diversity score of 4/12, indicat-
ing a high prevalence of food insecurity in this popula-
tion. When we examined the change in BMI in
subgroups of those deemed to have a better or worse
diet, there were no differences in the response to the
supplementary food observed (table 5). Thus, we
found no evidence that those with a worse diet would
benefit more from an energy dense food than those
with a better diet.
Comparisons of clinical outcomes with other studies
Our findings are consistent with some previous obser-
vations of supplementary feeding with energy dense
foods in people with HIV. Severely malnourished
Malawian children with HIV who received fortified
spread had greater weight-for-height improvement
than those receiving corn-soy blend.15 Adults with
AIDS in urban Malawi given vegetable oil and corn-
soy blend had greater improvement in BMI than those
receiving corn-soy blend alone.12 Findings from an
antiretroviral therapy programme in rural Malawi
that provided corn-soy blend as a supplementary
food in 2003 and fortified spread in 2004 indicate that
patients receiving fortified spread had greater weight
gain (1.5 v 0.8 kg/month; P=0.04) (Kaliwo G. Use of
RUTF in Thyolo district. CTC workshop, 25 June
2004, Lilongwe, Malawi). Our study is novel in that it
provides evidence that an energy dense food is asso-
ciated with improved recovery from wasting, though
our results need confirmation in other populations
with HIV.
Our data do not show a survival benefit associated
with either of the supplementary foods. As the study
was underpowered to detect differences in survival
smaller than 5%, we might have failed to detect a
small survival benefit during the intervention period.
Furthermore, as low BMI is an independent risk factor
for death,8 24 25 surviving patients who received supple-
mentary fortified spread, and who are more likely to
have a higher BMI, might have a better prognosis as
they continue antiretroviral therapy.
In our high risk study population we observed a
mortality rate of 27% in the first 14 weeks of anti-
retroviral therapy. High early mortality rates are com-
mon in antiretroviral therapy programmes in sub-
SaharanAfrica. In a study from ruralMalawi, themor-
tality rate in the first threemonths of antiretroviral ther-
apy was 26% in patients with severe malnutrition.8 In
another rural district of Malawi the mortality was
14.6% among all patients in the first six months, and
among those with BMI <18.5 the relative risk of death
was 3.56.24 The three month mortality among all
patients starting antiretroviral therapy in studies from
Senegal, Uganda, and Zambia was 7.6%, 6.4%, and
6.3%, respectively. Low BMI was identified as a risk
factor of death in all three studies, increasing the risk
of death by two to threefold.25-27 The high mortality
rate seen in our study highlights the importance of
wasting as a risk factor for death in people with HIV
starting antiretroviral therapy.
One difference between our study and the previous
reports was the irregular availability of co-trimoxazole
prophylaxis in Blantyre. A study fromMalawi showed
that co-trimoxazole prophylaxis can reduce earlymor-
tality during antiretroviral therapy,28 and indeed the
regression analysis in our study indicated that the
absence of co-trimoxazole prophylaxis was a strong
risk factor for death. This suggests that invasive bacter-
ial infections might have been an important cause of
mortality, an observation found in other studies of
early mortality on antiretroviral therapy from sub-
Saharan Africa.27 29 30 The high mortality rate in our
study might also have been because of undiagnosed
opportunistic infections present at enrolment. Tuber-
culosis is highly prevalent in Malawi, often presents
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Fig 2 | Analysis of rate of BMI change for fortified spread v
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Table 5 | Mean (SD) change in BMI after 14 weeks stratified by
quality of initial diet
Fortified spread Corn-soy blend
Animal products:
None consumed yesterday 2.1 (1.8) (n=113) 1.6 (1.6) (n=124)
Consumed yesterday 2.5 (2.0) (n=43) 1.9 (1.6) (n=42)
P value 0.17 0.37
No of different foods consumed yesterday:
0-6 2.2 (1.6) (n=41) 1.7 (1.6) (n=55)
7-9 2.1 (2.2) (n=53) 1.6 (1.7) (n=59)
10-20 2.2 (1.7) (n=62) 1.5 (1.6) (n=52)
P value 0.97 0.83
Dietary diversity score19:
1 (lowest)-2 2.0 (1.9) (n=56) 1.8 (0.4) (n=56)
3 2.3 (1.8) (n=54) 1.4 (1.6) (n=52)
4-12 2.2 (2.0 (n=46) 1.7 (1.6) (n=58)
P value 0.85 0.49
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atypically in patients with advanced immune suppres-
sion, and can give a clinical picture of wasting syn-
drome. It is an important cause of mortality in the
first six months of antiretroviral therapy in patients in
sub-Saharan Africa.31 At the start of treatment ema-
ciated patientsmight benefit frommore careful clinical
screening for opportunistic infections, particularly
tuberculosis. In addition, the effect of supplementary
feeding on mortality might be more remarkable in a
clinical setting where optimal management of oppor-
tunistic infections takes place.
The mean increase in CD4 count of 157 cells × 106/l
among surviving participants compares favourably
with data in other reports from sub-Saharan Africa;
similar increases were reported one year after starting
antiretroviral therapy in Malawi and Zambia.24 25
Cost comparisons
The corn-soy blend provided in our study cost $5.40
(£3.58, €4.06) per patient per month, while fortified
spread was three times as expensive at $16. The Mala-
wian government obtains the first line antiretroviral
therapy for $15 per patient per month. About a third
of all adults starting antiretroviral therapy in Blantyre
are wasted, so provision of supplementary food is a
considerable expense. We did not measure the long
term clinical benefits of supplementary feeding in this
study. Formal cost benefit analyses are required to
determine whether supplementary feeding strategies
are cost effective when compared with other elements
of clinical care given to those with HIV in sub-Saharan
Africa.
We have shown that an energy dense supplement
given to wasted adults starting antiretroviral therapy
promotes better nutritional recovery in 14 weeks. Fol-
low-up over a longer period of time is warranted to
determine if the anthropometric benefits conferred
by specialised energy dense supplements will lead to
improved clinical outcomes.
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